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Introduction
Candida parapsilosis was the third most isolated pathogen among Candida species in both North America and Taiwan. 1, 2 According to an epidemiological study in North America, C. parapsilosis accounted for 15.9% of all isolated organisms from 3648 patients. 2 It is higher in some hospital services, such as neonatal intensive care units, where it accounts for 30.6% of all isolated Candida species from neonatal intensive care unit patients in North America. 2 In the epidemiological study in Taiwan, C. parapsilosis remains the third most frequent Candida species. Candida albicans accounts for 50% of candidemia, whereas C. parapsilosis accounts for about 10% of the candidemia. 1 In addition, C. parapsilosis accounts for 47.8% of neonatal candidemia, based on a study that enrolled 46 neonates in Taiwan from 1994 to 1997. 3 According to a review article published in 2008, the mortality rate of C. parapsilosis bloodstream infections was 28.5%. 4 C. parapsilosis is a normal human commensal, which is often isolated from hand skin. It presents an oval, round, or cylindrical shape while appearing creamy, white, shiny, and smooth or wrinkled on Sabouraud dextrose agar. 5 Intact human skin limits the pathogenicity of C. parapsilosis. It is notorious for its affinity for catheter or prosthetic materials, capacity for forming biofilm and ability to grow in hyperalimentation solution. 6 A study in Spain revealed that the risk factors of C. parapsilosis infection include vascular catheterization, previous antibiotics history, previous immunosuppressive therapy, malignancy, transplant receipt, neutropenia, and previous colonization. 7 Several articles described the outbreak of C. parapsilosis infections either in neonate or adult intensive care units. Molecular typing methods revealed a link between hand carriage of C. parapsilosis from health care workers and the pathogen of the patients. Hand hygiene thus plays an important role in the prevention of the outbreak of C. parapsilosis infections. 4, 6, 8, 9 With regard to the increasing incidence of C. parapsilosis, its correlation with a high mortality rate and association with hand hygiene, it is important to conduct further research regarding C. parapsilosis.
Materials and methods

Study population
A retrospective study was conducted at a 2200-bed tertiary teaching hospital with burn care and solid organ transplantation facilities, but without bone marrow transplantation facilities in northern Taiwan. We enrolled the patients whose blood culture yielded C. parapsilosis during hospitalization from June 2008 to June 2012. The medical records of patients were reviewed, and data such as demographic characteristics, medical history, invasive procedures, medications, laboratory data, and outcomes were collected for analysis. We also have reviewed medical literature for comparison of C. parapsilosis in vitro antimicrobial susceptibility.
Inclusion criteria
C. parapsilosis bloodstream infection was defined as the presence of a positive blood culture of C. parapsilosis with concomitant signs and symptoms of infection. 10 C. parapsilosis bloodstream infection was considered to be health care-associated infections if it occurred more than 48 hours after admission. 11 If multiple episodes of C. parapsilosis bloodstream infection occurred in the same patient during the study period, the patient was included as a study participant using only the first episode of candidemia. 12 In the study period, a total of 77 patients whose blood culture yielding C. parapsilosis met the inclusion criteria.
Definition of terms
Death was considered to be attributable to C. parapsilosis bloodstream infection if any of the following was noted during the same hospital stay: death within 7 days after a positive blood culture for C. parapsilosis; absence of any cause of fatality; death in the presence of clinical evidence of persistent candidiasis (e.g., persistent fever, hypotension, or positive cultures for C. parapsilosis at clinically involved sites, such as peritoneal fluid, renal abscess, or endophthalmitis); autopsy evidence of disseminated candidiasis; or cause of death as C. parapsilosis bloodstream infection on the death certificate. 13, 14 The patient was considered a survivor of C. parapsilosis bloodstream infection if either of the following was noted regarding the same hospital stay: survival at discharge or improvement of C. parapsilosis bloodstream infection associated symptoms without recurrence within 30 days.
The incidence of candidemia was defined as the number of cases of candidemia per 1000 inpatient-days. 15 Defined daily dose is a statistical measure of drug consumption, defined by the World Health Organization. It is used to standardize the comparison of drug usage between different drugs or between different health care environments.
Species identification and antifungal susceptibility testing
Blood samples were tested daily for microbial growth using the BACTEC FX system (Becton Dickinson Diagnostic Instrument Systems, Sparks, MD, USA). Organisms were initially identified by germ tube analysis and colony morphology on Sabouraud dextrose agar. If necessary, they were determined using a VITEK 2 yeast identification card (bioMérieux SA, Marcy-l'Etoile, France). In this study, susceptibility testing of isolates was performed using eight antifungal agents (voriconazole, posaconazole, itraconazole, fluconazole, caspofungin, micafungin, anidulafungin, and amphotericin B) with a Sensititre YeastOne Colorimetric Antifungal Panel used according to the manufacturer's instructions. Susceptibilities of C. parapsilosis to the above antifungal agents were read according to the interpretative breakpoints approved by the European Committee on Antimicrobial Susceptibility Testing and the Clinical Laboratory Standards Institute for susceptibility testing of Candida species. 16 
Statistical analysis
Univariate analyses were used to identify the risk factors associated with candidemia-related death. A Pearson's Chi square test or Fisher's exact two-tailed test was used to examine nominal data, and the unpaired Student t test was used for continuous data. A p value of <0.05 was considered statistically significant. The independent predictors of candidemia-associated mortality were identified by stepwise logistic regression of multivariate analysis for the significant risk factors on the univariate analyses. SPSS for Windows version 21.0 (SPSS Inc., Chicago, IL, USA) software was used for statistical analysis. Linear regression analysis was used to analyze the trend in annual consumption of antifungal agents and the incidence of patients with candidemia over time. Pearson's product moment correlation coefficient was used to determine the relationship between annual consumption of antifungal agents and the trend in candidemia incidence. A p value of <0.05 was considered statistically significant.
Results
In Table 1 , the incidence levels of candidemia in our hospital from 2008 to 2012 are listed. The overall incidence of candidemia showed a significant increase (p < 0.05). The incidence of individual Candida species did not significantly increase by year. However, the incidence of C. parapsilosis showed a mild decrease although it did not reach statistical significance.
A total of 77 episodes were identified retrospectively in 77 patients with C. parapsilosis candidemia. The univariate analysis of risk factors of C. parapsilosis candidemiaassociated mortality in 77 patients is summarized in Table 2 . About 58% (45/77) were male, and the mean age was 50.5 AE 30.9 years. About 25% (19/77) of the patients Table 3 , showed that patients with malignancy had a higher odds ratio in terms of mortality (p Z 0.045). A total of 75 patients (75/77) had a central lineassociated route when they acquired a C. parapsilosis bloodstream infection. Five patients had a Hickman catheter, 26 patients had a port-A, and 44 patients had a central venous catheter (CVC), which included 18 patients with femoral CVC. However, the kind of catheter used did not contribute to mortality ( Table 2) .
The minimal inhibitory concentration (MIC) of 67 C. parapsilosis in our study, which were identified by YeastOne commercial disk, is summarized in Table 4 . The MIC 50 /MIC 90 of fluconazole was 1/2 (range 0.25e8), amphotericin B was 1/1 (range 0.25e1), anidulafungin was 1/2 (range 0.12e2), micafungin was 1/2 (range 0.25e4), caspofungin was 0.5/1 (range 0.25e1), voriconazole was 0.008/0.15 (range 0.008e0.15), posaconazole was 0.03/ 0.06 (range 0.015e0.12), and itraconazole was 0.06/0.12 (range 0.015e0.25). The C. parapsilosis susceptibility rate to fluconazole was 95.5%, whereas the resistance rate was 3%. We included papers mentioning the fluconazole resistance rate of C. parapsilosis and those giving full coverage of antifungal agents. The result is also listed in Table 4 .
The correlation between the annual consumption of antifungal agents and the incidence of C. parapsilosis bloodstream infection was calculated using Pearson's product moment correlation coefficient (results shown in Table 5 ). The incidence of C. parapsilosis bloodstream infection increased, whereas the annual consumption of echinocandin increased during the study period. C. parapsilosis bloodstream infection showed a moderate positive correlation with the use of echinocandin, but this correlation was not statistically significant (Pearson correlation Z 0.614, p Z 0.271).
Discussion
The incidence of all candidemia cases in the hospital was 0.25 per 1000 patient-days, which shows a significant increase from 2008 to 2012; the incidence also increased significantly from 0.10 to 0.15 per 1000 patient-days from 1999 to 2006 in Taiwan. 1 In the meantime, the incidence of candidemia ranged from 0.45 to 0.46 per 1000 admissiondays in America and ranged from 0.2 to 0.38 in Europe. 17 Ruan and Hsueh 17 mentioned that the incidence of candidemia from 1980 to the end of 1990s increased. This was followed by a relatively stable period in Taiwan, but it continued to increase significantly in the 2000s. 17 The distribution of Candida species shows regional differences. 18 In this study, C. albicans (49.0%) was the most frequently isolated species, followed by C. tropicalis (15.5%), C. glabrata (15.2%), and C. parapsilosis (10.8%). The rate of isolated C. parapsilosis was 13.3%, which is close to the average rate in the Asia-Pacific area (13.7%), but lower than the global average (17.2%) from 2008 to 2009. 19 Three studies during 1994 to 2000 from northern Taiwan reported the rate of isolated C. parapsilosis to be around 11.2e17.5%. 20e22 Pfaller et al 23, 24 reported global data showing that the rate of isolated C. parapsilosis from 1992 to 2001 was 13.1% and 15%. The distribution in the hospital was similar to that reported in the Asia-Pacific area, and although C. tropicalis was higher than C. glabrata, the rates of the following three non-albicans Candida spp. were close. C. parapsilosis is a common skin colonizer. It is most often isolated from neonates and children and related to intravenous instrumentation. The risk factors of patients who developed C. parapsilosis bloodstream infections include prolonged use of catheter or indwelling device, hyperalimentation solution infusion, gastrointestinal surgery, presence of immune compromising conditions such as AIDS, recent chemotherapy or use of immune compressive agents, previous colonization, previous antibiotics treatment, or previous antifungal agent treatment. 4 Chen et al 25 found that patients with C. parapsilosis bloodstream infections had higher blood albumin levels, lower Sequential Organ Failure Assessment scores, and frequently those who had total parental nutrition infusions would have lower mortality rates. In our study, the mortality rate was 41.6%, which is higher than that (28.5%) reported in a review article in 2008 or in 2012 (30%). 2, 4 The risk factors of mortality included those patients with any malignancy or presence of a metastatic tumor. By contrast, patients younger than 18 years had lower mortality rates. Furthermore, in multivariate logistical regression analysis, patients with malignancy had a higher odds ratio in terms of mortality. However, the drug selection, total parental nutrition infusion, type of catheter, or the site of CVC did not increase the risk of mortality. Andes et al 26 report that echinocandin, CVC removal, and Acute Physiology and Chronic Health Evaluation II score were independently associated with mortality in non-albicans Candida species infections, but only disease severity predicted the survival of patients with C. parapsilosis and C. tropicalis infections. In our study, the results supported similar conclusionsdthat underlying comorbidity and malignancy were the factors leading to death. C. parapsilosis bloodstream infection was merely a confounding accident. The Infectious Diseases Society of America guidelines for the management of candidiasis in 2009 suggested fluconazole for nonneutropenic patients with C. parapsilosis infections, and fluconazole or liposomal amphotericin B for neutropenic patients. The susceptibility of C. parapsilosis to echinocandin was susceptible to resistance, even though in vitro resistance was uncommon. 27 The in vitro activity of antifungal agents against C. parapsilosis from this study and other articles are summarized in Table 4 . 28e37 About 3% of isolated C. parapsilosis in our study were resistant to fluconazole. This rate is similar to the global data. However, a high resistance rate of fluconazole was noted in China. The authors of two articles mentioned the cross resistance between fluconazole and voriconazole, and suggested using non-azole antifungal agents and consistently monitoring susceptibility. 32, 33 Echinocandin is a new class of antifungal agents. The echinocandin MICs of C. parapsilosis are higher than those of other Candida species. In our study, only one isolated C. parapsilosis was intermediate to micafungin. The other isolates were susceptible to in vitro echinocandin. However, the survival rate of patients receiving echinocandin was lower than that of patients receiving fluconazole (46.2% vs. 59.1%). Amphotericin B was traditionally the most commonly prescribed antifungal agent. The reported resistance rate of C. parapsilosis to amphotericin B was 2e3%. 4 In our study, no isolated C. parapsilosis was resistant to amphotericin B in vitro. The clinical response was better compared with other agents. However, because of its nephrotoxicity and the high cost of liposomal amphotericin B, their annual consumption was on the decrease. In our study, fluconazole remains the drug of choice to treat C. parapsilosis bloodstream infections.
Caspofungin was introduced to our hospital in 2003, followed by micafungin in 2009, and then anidulafungin in 2011. It is hypothesized that the increasing use of antifungal agents, such as fluconazole, increases the selection pressure on non-albicans Candida species. However, conflicting results have been reported, and thus the hypothesis remains controversial. 17 Given the high MIC of C. parapsilosis, some articles mention the selection pressure associated with the increasing use of echinocandin. 2 However, Lai et al 15 reported a significant negative correlation between the incidence of C. parapsilosis infection and the use of echinocandin and voriconazole. In our study, C. parapsilosis bloodstream infection showed a moderate positive correlation with the use of echinocandin, but this correlation was not statistically significant. Many factors influence the incidence of C. parapsilosis bloodstream infection. The advocacy of hand hygiene campaign started in our hospital in 2009. Furthermore, the CVC care bundle was launched in the intensive care unit in our hospital in 2010. The reinforcement of infection control would reduce the infection rate of C. parapsilosis. Although the use of antifungal agents is not the only factor influencing the incidence of C. parapsilosis infection, our study does not support the hypothesis that increasing use of echinocandin increases the incidence of C. parapsilosis infection.
Underlying comorbidity and malignancy were factors leading to death in patients with C. parapsilosis bloodstream infection. Catheter removal did not influence the mortality rate. The survival rate of patients receiving echinocandin was lower than that in the group receiving fluconazole. Fluconazole remains the drug of choice to treat C. parapsilosis bloodstream infections.
